General Information
Dasatinib monohydrate is a kinase inhibitor indicated for the treatment of ‘ newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase ‘ adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib ‘ adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.
About the API
Systematic name
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
Trade name(s)
Sprycel
Molecular Formula
C22H26ClN7O2S •H2O
Molecular Weight
506.02082 g/mol
Physical properties
Crystalline
Therapeutic category
Antineoplastic and Immunomodulating Agents
Available formulations
Oral Solid
Regulations
CADIFA
US DMF
CADIFA
US DMF